Literature DB >> 3261325

Use of mefloquine in epileptic patients.

P Jallon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3261325      PMCID： PMC1033093          DOI： 10.1136/jnnp.51.5.732

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  3 in total

1.  Clinical pharmacological aspects of valproate sodium.

Authors:  K Wulff; H Flachs; A Würtz-Jorgensen; L Gram
Journal:  Epilepsia       Date:  1977-06       Impact factor: 5.864

2.  [Making good use of mefloquine].

Authors:  H Félix; M Rosenheim; M Danis
Journal:  Bull Soc Pathol Exot Filiales       Date:  1985

3.  A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand.

Authors:  T Harinasuta; D Bunnag; W H Wernsdorfer
Journal:  Bull World Health Organ       Date:  1983       Impact factor: 9.408
  3 in total
  4 in total

1.  [Use-risk consideration of anti-infective agents from the point of view of the licensing authority].

Authors:  W Christ; B Esch
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Carboxymefloquine, the major metabolite of the antimalarial drug mefloquine, induces drug-metabolizing enzyme and transporter expression by activation of pregnane X receptor.

Authors:  Rita Piedade; Stefanie Traub; Andreas Bitter; Andreas K Nüssler; José P Gil; Matthias Schwab; Oliver Burk
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

Review 3.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 4.  Adverse effects of antimalarials. An update.

Authors:  G A Luzzi; T E Peto
Journal:  Drug Saf       Date:  1993-04       Impact factor: 5.606
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.